Literature DB >> 18487563

Problems and solutions in the evaluation of hormone receptors in breast cancer.

D Craig Allred.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18487563     DOI： 10.1200/JCO.2007.15.7800

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma.

Authors:  Tamanna Parvin; Chhanda Das; Manoj Choudhury; Bitan Kumar Chattopadhyay; Madhumita Mukhopadhyay
Journal:  Indian J Surg Oncol       Date:  2018-11-30

Review 2.  Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.

Authors:  Viroj Boonyaratanakornkit; Nalo Hamilton; Diana C Márquez-Garbán; Prangwan Pateetin; Eileen M McGowan; Richard J Pietras
Journal:  Mol Cell Endocrinol       Date:  2017-11-14       Impact factor: 4.102

3.  Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.

Authors:  Jennifer J Griggs; Ann S Hamilton; Kendra L Schwartz; Weiqiang Zhao; Paul H Abrahamse; Dafydd G Thomas; Julie M Jorns; Rachel Jewell; Maria E Sibug Saber; Reina Haque; Steven J Katz
Journal:  Breast Cancer Res Treat       Date:  2016-11-29       Impact factor: 4.872

4.  More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin.

Authors:  Lev M Berstein; Marina P Boyarkina; Evgenia V Tsyrlina; Elena A Turkevich; Vladimir F Semiglazov
Journal:  Med Oncol       Date:  2010-05-20       Impact factor: 3.064

5.  Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies.

Authors:  Jennifer Zeng; Salvatore Piscuoglio; Gitika Aggarwal; Joanna Magda; Maria A Friedlander; Melissa Murray; Muzaffar Akram; Jorge S Reis-Filho; Britta Weigelt; Marcia Edelweiss
Journal:  Cancer Cytopathol       Date:  2019-12-28       Impact factor: 5.284

6.  A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors.

Authors:  Jyothi S Prabhu; Aruna Korlimarla; Krisha Desai; Annie Alexander; Rohini Raghavan; Ce Anupama; Nandini Dendukuri; Suraj Manjunath; Marjorrie Correa; N Raman; Anjali Kalamdani; Msn Prasad; K S Gopinath; B S Srinath; T S Sridhar
Journal:  J Cancer       Date:  2014-01-23       Impact factor: 4.207

7.  Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Ahmed M M Youssef; Fatima Al-Tarawneh; Sameeh Al-Sarayreh; Ghadeer H Almuhaisen; Anas O Satari; Jehad Al-Shuneigat; Hamzeh Mohammad Alrawashdeh
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-10-05

8.  Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay.

Authors:  D Mouttet; M Laé; M Caly; D Gentien; S Carpentier; H Peyro-Saint-Paul; A Vincent-Salomon; R Rouzier; B Sigal-Zafrani; X Sastre-Garau; F Reyal
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

9.  Concordance between Immunohistochemistry and Microarray Gene Expression Profiling for Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Statuses in Breast Cancer Patients in Lebanon.

Authors:  Ghina B Fakhri; Reem S Akel; Maya K Khalil; Deborah A Mukherji; Fouad I Boulos; Arafat H Tfayli
Journal:  Int J Breast Cancer       Date:  2018-05-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.